Last reviewed · How we verify
NCT05392348
Human Gut Microbiota and microRNA Expression
NA trial testing stachyose in Gut Microbiota in 36 participants. Status unknown.
25 June 2022
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 36 |
| Start date | 25 May 2022 |
| Primary completion | 25 June 2022 |
| Estimated completion | 30 June 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- stachyose
- Maltodextrin (MALTODEXTRIN) — full drug profile →
Conditions studied
- Gut Microbiota — all drugs for Gut Microbiota →
- microRNA — all drugs for microRNA →
Sponsor
Xijing Hospital
Who can join
Adults 18 to 30, any sex, with Gut Microbiota or microRNA. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, stachyose was used as an intervention factor. We will evaluate changes in fecal gut microbiota and miRNA expression profiles in subjects under stachyose intervention
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Structural characteristics of <i>Ficus carica</i> L. dietary fibers and their in vitro fermentation properties in modulating gut microbiota and metabolites.
Wang Y, Li J, Aihaiti A, Shataer D, et al · · 2026 · PMID 41624577 · DOI 10.1016/j.fochx.2026.103588
Verify or expand the search:
- PubMed search for NCT05392348
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gut Microbiota
Currently open trials in the same condition.
- NCT07289581 — Effect of Treatment With Butyric Acid in Anorexia Nervosa · NA · active not recruiting
- NCT07214428 — Effects of Grape Powder on Psychological Distress and Gut Microbiota in College Students · NA · active not recruiting
- NCT07052071 — Impact of Transcatheter Aortic Valve Implantation (TAVI) on the Gut Microbiota in Patients With Aortic Valve Stenosis · recruiting
- NCT06935435 — Effects of Distinct Nebraska-Dry Bean Market Classes on Gut Microbiota · NA · active not recruiting
- NCT06854536 — A Study on the Changes and Prognosis of Intestinal Microbiota and Function in Infants With Food Allergies · active not recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05392348 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 26 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05392348.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing